BTIG Capital upgraded Apple to a buy, and Amazon was downgraded to neutral at JPMorgan, reports CNBC's Seema Mody.
Shervin Pishevar, Menlo Ventures Advisors, discusses how innovation will impact the next decade, as top tech business leaders gathering today at the "F.ounder's" conference in New York.
If there is a pullback in the markets, will this be a catalyst for Apple's stock? CNBC's Seema Mody has the details.
Vasu Menon, Vice President of Wealth Management Singapore at OCBC Bank, warns that volatility should be expected going forward and a correction of 5% would be ideal entry point into the markets.
Google has overtaken Apple as the top U.S. mutual fund holding, reports CNBC's Seema Mody.
The Nasdaq hit a 12-year high but it is still more than 30 percent off its all-time high, reports CNBC's Seema Mody.
CNBC's Seema Mody reports which stocks could help fuel the Nasdaq higher.
Nasdaq OMX Group said it will form a joint venture with SharesPost to establish a marketplace for private companies. The stock exchange operator will retain a majority stake in Nasdaq Private Market.
CNBC's Seema Mody reports the Nasdaq is trading above its key resistance level of 3,200. Apple is the best performing tech stock on the Nasdaq 100 since the dot com crash.
CNBC's Seema Mody reports the Nasdaq is still more than 30 percent away from its all-time intraday high. Google is hitting another all-time high today.
How much longer can the tech titan run? Colin Gillis, BGC Financial analyst, weighs in on what's driving Google's surge.
CNBC's Seema Mody reports which stocks are driving the rally, as the Nasdaq hits a fresh 12-year high.
CNBC's Seema Mody reports the latest from the Nasdaq, including shares of Monster Beverage are up after the company reported a 15 percent jump in quarterly sales.
Laszlo Biriny, Birinyi Associates, explains why he continues to look for more gains in the markets, but in an irregular pattern. And Jim Paulsen, Wells Capital Management, provides his perspective on how to invest in a choppy market.
CNBC's Seema Mody reports on big movers in Biotech after Affymax and Takeda recalled an anemia drug named Omontys.
Pros are heading to the sidelines worried that the Fed has shifted its view on stimulus. Is Jim Cramer among them?
Patrick Spencer, MD and director of international equity sales at Baird, tells CNBC why the market is in a stable, healthy state and investors shouldn't be too worried by Wednesday's blip in the US markets.
John Barr, Needham Growth Fund, explains why some small and mid-cap tech companies could provide the best investments opportunities now.
As the precious metal continues to lose steam, Cramer looks at where gold might be headed next and how to trade it.
As the Dow and the S&P 500 have both rallied 7 percent since the beginning of the year, the "Mad Money" host said investors need to change the way they're investing.